keyword
MENU ▼
Read by QxMD icon Read
search

Antiretroviral side effects

keyword
https://www.readbyqxmd.com/read/28028587/safety-of-zidovudine-lamivudine-scored-tablets-in-children-with-hiv-infection-in-europe-and-thailand
#1
Ali Judd
BACKGROUND: Zidovudine (ZDV) has been associated with risk of haematological toxicity. Safety data from clinical trials is generally limited to 48 weeks. We assessed the short- and mid-term toxicity of ZDV/lamivudine (3TC) fixed-dose combination scored tablets in HIV-infected children followed in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) network. METHODS: Fourteen cohorts provided data on patients <18 years of age taking ZDV/3TC scored tablets between 2008 and 2012...
December 27, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28008980/antiretroviral-treatment-with-efavirenz-disrupts-the-blood-brain-barrier-integrity-and-increases-stroke-severity
#2
Luc Bertrand, Levi Dygert, Michal Toborek
The introduction of antiretroviral drugs (ARVd) changed the prognosis of HIV infection from a deadly disease to a chronic disease. However, even with undetectable viral loads, patients still develop a wide range of pathologies, including cerebrovascular complications and stroke. It is hypothesized that toxic side effects of ARVd may contribute to these effects. To address this notion, we evaluated the impact of several non-nucleoside reverse transcriptase inhibitors (NNRTI; Efavirenz, Etravirine, Rilpivirine and Nevirapine) on the integrity of the blood-brain barrier, and their impact on severity of stroke...
December 23, 2016: Scientific Reports
https://www.readbyqxmd.com/read/28006001/detectable-viral-load-in-late-pregnancy-among-women-in-the-rwanda-option-b-pmtct-program-enrollment-results-from-the-kabeho-study
#3
Michelle M Gill, Heather J Hoffman, Emily A Bobrow, Placidie Mugwaneza, Dieudonne Ndatimana, Gilles F Ndayisaba, Cyprien Baribwira, Laura Guay, Anita Asiimwe
There are limited viral load (VL) data available from programs implementing "Option B+," lifelong antiretroviral treatment (ART) to all HIV-positive pregnant and postpartum women, in resource-limited settings. Extent of viral suppression from a prevention of mother-to-child transmission of HIV program in Rwanda was assessed among women enrolled in the Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV (Kabeho) Study. ARV drug resistance testing was conducted on women with VL>2000 copies/ml...
2016: PloS One
https://www.readbyqxmd.com/read/27993121/trimethyl-chitosan-improves-anti-hiv-effects-of-atripla-as-a-new-nano-formulated-drug
#4
Sepideh Shohani, Asghar Abdoli, Behzad Khansarinejad, Mehdi Shafiee Ardestani, Mohammad Salimi-Asl, Maryam Ghanbari, Mehrdad Sadeghi Haj, Rezvan Zabihollahi, Mahdieh Mondanizadeh
Background; highly active antiretroviral therapy (HAART) has been commonly used for HIV treatment. Its main drawbacks like drug resistance and side effects raised researcher's interest to find new approaches for its treatment. Trimethyl chitosan is one of the drug carriers which was introduced recently. Materials and Methods; the conjugated atripla-trimethyl chitosan was designed and characterized by zetasizer, AFM and FTIR techniques. The drug conjugation with trimethyl chitosan and cellular uptake of nano-conjugate were determined by spectrophotometry...
December 16, 2016: Current HIV Research
https://www.readbyqxmd.com/read/27964776/-since-both-of-us-are-using-antiretrovirals-we-have-been-supportive-to-each-other-facilitators-and-barriers-of-pre-exposure-prophylaxis-use-in-heterosexual-hiv-serodiscordant-couples-in-kisumu-kenya
#5
Rena C Patel, Gaelen Stanford-Moore, Josephine Odoyo, Maria Pyra, Imeldah Wakhungu, Keerthana Anand, Elizabeth A Bukusi, Jared M Baeten, Joelle M Brown
INTRODUCTION: Since 2015, the World Health Organization recommends pre-exposure prophylaxis (PrEP) for all persons at substantial risk for HIV, including HIV-uninfected partners in serodiscordant relationships in resource-limited settings. As PrEP moves from clinical trials to real-world use, understanding facilitators of and barriers to PrEP initiation and adherence is critical to successful PrEP implementation and rollout. METHODS: We conducted 44 in-depth individual or couple interviews with 63 participants (30 without HIV and 33 with HIV) enrolled in the Partners Demonstration Project in Kisumu, Kenya, between August and September 2014...
2016: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/27959728/effect-of-hiv-antibody-vrc01-on-viral-rebound-after-treatment-interruption
#6
MULTICENTER STUDY
Katharine J Bar, Michael C Sneller, Linda J Harrison, J Shawn Justement, Edgar T Overton, Mary E Petrone, D Brenda Salantes, Catherine A Seamon, Benjamin Scheinfeld, Richard W Kwan, Gerald H Learn, Michael A Proschan, Edward F Kreider, Jana Blazkova, Mark Bardsley, Eric W Refsland, Michael Messer, Katherine E Clarridge, Nancy B Tustin, Patrick J Madden, KaSaundra Oden, Sijy J O'Dell, Bernadette Jarocki, Andrea R Shiakolas, Randall L Tressler, Nicole A Doria-Rose, Robert T Bailer, Julie E Ledgerwood, Edmund V Capparelli, Rebecca M Lynch, Barney S Graham, Susan Moir, Richard A Koup, John R Mascola, James A Hoxie, Anthony S Fauci, Pablo Tebas, Tae-Wook Chun
Background The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention and treatment of HIV infection. We sought to determine whether passive administration of VRC01, a bNAb targeting the HIV CD4-binding site, can safely prevent or delay plasma viral rebound after the discontinuation of antiretroviral therapy (ART). Methods We conducted two open-label trials (AIDS Clinical Trials Group [ACTG] A5340 and National Institutes of Health [NIH] 15-I-0140) of the safety, side-effect profile, pharmacokinetic properties, and antiviral activity of VRC01 in persons with HIV infection who were undergoing interruption of ART...
November 24, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27939443/anxiety-symptoms-and-disorders-among-adults-living-with-hiv-and-aids-a-critical-review-and-integrative-synthesis-of-the-empirical-literature
#7
REVIEW
Charles Brandt, Michael J Zvolensky, Steven P Woods, Adam Gonzalez, Steven A Safren, Conall M O'Cleirigh
There are over 35 million people worldwide infected with the Human Immunodeficiency Virus (HIV) and its progression to Acquired Immunodeficiency Syndrome (AIDS; WHO, 2014). With the advent of combined antiretroviral therapy (i.e., cART) in 1996, persons living with HIV/AIDS (PLWHA) now have much longer life expectancies. However, living with HIV remains challenging, as it is associated with a number of significant and recurrent (chronic) stressors including physical pain, side effects of cART, social stigma, and discrimination, among other social stressors...
February 2017: Clinical Psychology Review
https://www.readbyqxmd.com/read/27930740/facilitators-and-barriers-of-antiretroviral-therapy-initiation-among-hiv-discordant-couples-in-kenya-qualitative-insights-from-a-pre-exposure-prophylaxis-implementation-study
#8
Rena C Patel, Josephine Odoyo, Keerthana Anand, Gaelen Stanford-Moore, Imeldah Wakhungu, Elizabeth A Bukusi, Jared M Baeten, Joelle M Brown
INTRODUCTION: The World Health Organization now recommends antiretroviral therapy (ART) initiation for all HIV-infected individuals regardless of CD4 cell count or disease status. Understanding the facilitators and barriers to initiation of and adherence to ART is essential to successful scale-up of "universal" ART. METHODS: To investigate facilitators and barriers to ART initiation, we conducted 44 in-depth individual or couple interviews with 63 participants (33 participants with HIV and 30 without HIV) already enrolled in a prospective implementation study of oral antiretroviral-based prevention in Kisumu, Kenya between August and September 2014...
2016: PloS One
https://www.readbyqxmd.com/read/27930607/counseling-framework-for-hiv-serodiscordant-couples-on-the-integrated-use-of-antiretroviral-therapy-and-pre-exposure-prophylaxis-for-hiv-prevention
#9
Jennifer F Morton, Connie Celum, John Njoroge, Agnes Nakyanzi, Imeldah Wakhungu, Edna Tindimwebwa, Snaidah Ongachi, Eric Sedah, Emmanuel Okwero, Kenneth Ngure, Josephine Odoyo, Nulu Bulya, Jessica E Haberer, Jared M Baeten, Renee Heffron
BACKGROUND: For HIV-serodiscordant couples, integrated delivery of antiretroviral therapy (ART) for HIV-positive partners and time-limited pre-exposure prophylaxis (PrEP) for negative partners virtually eliminates HIV transmission. Standardized messaging, sensitive to the barriers and motivators to HIV treatment and prevention, is needed for widespread scale-up of this approach. METHODS: Within the Partners Demonstration Project, a prospective interventional project among 1013 serodiscordant couples in Kenya and Uganda, we offered ART to eligible HIV-positive partners and PrEP to HIV-negative partners before ART initiation and through the HIV-positive partner's first 6 months of ART use...
January 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27927183/art-access-related-barriers-faced-by-hiv-positive-persons-linked-to-care-in-southern-ghana-a-mixed-method-study
#10
Augustine Ankomah, John Kuumuori Ganle, Margaret Yaa Lartey, Awewura Kwara, Priscilla Awo Nortey, Michael Perry Kweku Okyerefo, Amos Kankponang Laar
BACKGROUND: Timely and enduring access to antiretroviral therapy (ART) by HIV-infected individuals has been shown to substantially reduce HIV transmission risk, HIV-related morbidity and mortality. However, there is evidence that in addition to limited supply of antiretrovirals (ARVs) and linkage to ART in many low-income countries, HIV+ persons often encounter barriers in accessing ART-related services even in contexts where these services are freely available. In Ghana, limited research evidence exists regarding the barriers HIV+ persons already linked to ART face...
December 7, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27923009/counseling-framework-for-hiv-serodiscordant-couples-on-the-integrated-use-of-antiretroviral-therapy-and-pre-exposure-prophylaxis-for-hiv-prevention
#11
Jennifer F Morton, Connie Celum, John Njoroge, Agnes Nakyanzi, Imeldah Wakhungu, Edna Tindimwebwa, Snaidah Ongachi, Eric Sedah, Emmanuel Okwero, Kenneth Ngure, Josephine Odoyo, Nulu Bulya, Jessica E Haberer, Jared M Baeten, Renee Heffron
BACKGROUND: For HIV-serodiscordant couples, integrated delivery of antiretroviral therapy (ART) for HIV-positive partners and time-limited pre-exposure prophylaxis (PrEP) for negative partners virtually eliminates HIV transmission. Standardized messaging, sensitive to the barriers and motivators to HIV treatment and prevention, is needed for widespread scale-up of this approach. METHODS: Within the Partners Demonstration Project, a prospective interventional project among 1013 serodiscordant couples in Kenya and Uganda, we offered ART to eligible HIV-positive partners and PrEP to HIV-negative partners before ART initiation and through the HIV-positive partner's first 6 months of ART use...
January 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27919841/prevalence-of-non-adherence-to-highly-active-antiretroviral-therapy-and-its-related-clinical-and-therapeutic-factors-in-ouagadougou-burkina-faso
#12
O Guira, D S R Kaboré, G Dao, N Zagré, T M Zohoncon, V Pietra, J Simporé
: Introduction : Non-adherence to highly active antiretroviral therapy is deleterious in HIV/AIDS programs. This study contributes to the identification of its frequency and of the clinical and therapeutic factors that determine it. Material and methods : This cross-sectional study took place from December 15, 2013, to February 18, 2014, at the Saint Camille health care center and the Pietro Annigoni biomolecular research center in Ouagadougou. It includes adults who had been receiving antiretroviral therapy for at least three months and agreed to participate...
December 5, 2016: Médecine et Santé Tropicales
https://www.readbyqxmd.com/read/27910750/antiretroviral-agents-looking-for-the-best-possible-chemotherapeutic-options-to-conquer-hiv
#13
Tahir Farooq, Arruje Hameed, Kanwal Rehman, Muhammad Ibrahim, Muhammad Imran Qadir, Muhammad Sajid Hamid Akash
For the last thirty years, ongoing efforts have revolutionized the antiretroviral therapy, which changed human immunodeficiency virus (HIV) infections from terrifying lethal diseases to chronic conditions. However, many challenges, like emergence of drug resistance, limited the scope of activity of currently existing anti-HIV agents. Quite often severe side effects and lifelong dependency are the major concerns of present era. All these issues have compelled the scientists to reconsider and refine the current therapies and also contemplate the pivotal priorities for the developments of novel therapeutic paradigms...
2016: Critical Reviews in Eukaryotic Gene Expression
https://www.readbyqxmd.com/read/27906007/what-happens-to-cardiovascular-system-behind-the-undetectable-level-of-hiv-viremia
#14
REVIEW
Gabriella d'Ettorre, Giancarlo Ceccarelli, Paolo Pavone, Pietro Vittozzi, Gabriella De Girolamo, Ivan Schietroma, Sara Serafino, Noemi Giustini, Vincenzo Vullo
Despite the combined antiretroviral therapy has improved the length and quality of life of HIV infected patients, the survival of these patients is always decreased compared with the general population. This is the consequence of non-infectious illnesses including cardio vascular diseases. In fact large studies have indicated an increased risk of coronary atherosclerotic disease, myocardial infarction even in HIV patients on cART. In HIV infected patients several factors may contribute to the pathogenesis of cardiovascular problems: life-style, metabolic parameters, genetic predisposition, viral factors, immune activation, chronic inflammation and side effects of antiretroviral therapy...
April 27, 2016: AIDS Research and Therapy
https://www.readbyqxmd.com/read/27905840/combining-cell-and-gene-therapy-in-an-effort-to-eradicate-hiv
#15
Thor A Wagner
More than 30 million people are infected with HIV, and HIV remains the fifth leading cause of disability-adjusted life years worldwide. Antiretroviral therapy (ART) dramatically decreases mortality rate, but there are side effects, long-term toxicities, expenses, stigmas, and inconveniences associated with chronic treatment, and HIV-infected individuals on ART have an increased risk of malignancies, cardiovascular disease, neurologic disease, and shortened life expectancy. Therefore, a cure for HIV remains an important goal...
December 2016: AIDS Patient Care and STDs
https://www.readbyqxmd.com/read/27904105/evaluation-of-the-lipid-concentrations-after-switching-from-antiretroviral-drug-tenofovir-disoproxil-fumarate-emtricitabine-to-abacavir-sulfate-lamivudine-in-virologically-suppressed-human-immunodeficiency-virus-infected-patients
#16
Hirotaka Arae, Masao Tateyama, Hideta Nakamura, Daisuke Tasato, Kaoru Kami, Kyoko Miyagi, Saori Maeda, Hitoshi Uehara, Makiko Moromi, Katsunori Nakamura, Jiro Fujita
Objective Recently, tenofovir disoproxil fumatate (TDF)-related side effects, such as renal nephrotoxicity and reduction of bone mineral density, have been reported. Consequently, increased switching from fixed-dose tablet TDF and emtricitabine (TDF/FTC) to abacavir and lamivudine (ABC/3TC) has occurred. Interestingly, while TDF has a lipid-lowering property, one of the ABC-related side effects is hyperlipidemia. Therefore, such switching could cause lipid elevation. To evaluate the change in lipid levels associated with switching from TDF/FTC to ABC/3TC in virologically-suppressed human immunodeficiency virus (HIV)-infected patients...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27900502/values-and-preferences-on-the-use-of-oral-pre-exposure-prophylaxis-prep-for-hiv-prevention-among-multiple-populations-a-systematic-review-of-the-literature
#17
Florence M Koechlin, Virginia A Fonner, Sarah L Dalglish, Kevin R O'Reilly, Rachel Baggaley, Robert M Grant, Michelle Rodolph, Ioannis Hodges-Mameletzis, Caitlin E Kennedy
Daily oral pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by HIV-negative people to prevent HIV infection. WHO released new guidelines in 2015 recommending PrEP for all populations at substantial risk of HIV infection. To prepare these guidelines, we conducted a systematic review of values and preferences among populations that might benefit from PrEP, women, heterosexual men, young women and adolescent girls, female sex workers, serodiscordant couples, transgender people and people who inject drugs, and among healthcare providers who may prescribe PrEP...
November 29, 2016: AIDS and Behavior
https://www.readbyqxmd.com/read/27898736/long-term-antiretroviral-treatment-adherence-in-hiv-infected-adolescents-and-adults-in-uganda-a-qualitative-study
#18
Seth C Inzaule, Raph L Hamers, Cissy Kityo, Tobias F Rinke de Wit, Maria Roura
BACKGROUND: Long-term success of HIV antiretroviral therapy requires near-perfect adherence, maintained throughout one's lifetime. However, perceptions towards ART and patterns of adherence may change during the life course. We assessed challenges to long-term adherence in adolescents and adults in three regional HIV treatment centers in Uganda. METHODS: We conducted 24 in-depth interviews and 2 focus group discussions with a total of 33 health-care providers and expert clients (HIV patients on long-term ART who assist with adherence support of fellow patients)...
2016: PloS One
https://www.readbyqxmd.com/read/27869733/antiviral-therapy-by-hiv-1-broadly-neutralizing-and-inhibitory-antibodies
#19
REVIEW
Zhiqing Zhang, Shaowei Li, Ying Gu, Ningshao Xia
Human immunodeficiency virus type 1 (HIV-1) infection causes acquired immune deficiency syndrome (AIDS), a global epidemic for more than three decades. HIV-1 replication is primarily controlled through antiretroviral therapy (ART) but this treatment does not cure HIV-1 infection. Furthermore, there is increasing viral resistance to ART, and side effects associated with long-term therapy. Consequently, there is a need of alternative candidates for HIV-1 prevention and therapy. Recent advances have discovered multiple broadly neutralizing antibodies against HIV-1...
November 18, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27867446/-so-far-it-s-been-choosing-which-side-effects-i-want-or-i-can-deal-with-a-grounded-theory-of-hiv-treatment-side-effects-among-people-living-with-hiv
#20
Marilou Gagnon, Dave Holmes
Despite the availability of new antiretroviral drugs and the simplification of treatment options, side effects continue to affect people living with HIV. In this paper, we present the findings of a grounded theory study designed to gain a critical understanding of the experience of side effects. Three main categories emerged from the data: the side effects, the experience, and the connections. The first category suggests that we need to change how we think about side effects in order to take into account the context in which they are experienced as well as the types and nature of side effects...
January 1, 2016: Aporia
keyword
keyword
80811
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"